1. Scrip
  2. >>Therapy Areas

AbbVie Bails On Harpoon’s Multiple Myeloma Drug Amid Highly Competitive Environment

 
• By Alaric DeArment

Harpoon said it plans to complete the Phase I study of its anti-BCMA immuno-oncology agent HPN217 and use the data to support the next phase of development for the drug.

AbbVie decided not to exercise its option for Harpoon's multiple myeloma drug candidate • Source: Shutterstock

Harpoon Therapeutics’s BCMA-directed T-cell engager candidate for multiple myeloma faces a murky path ahead following a decision by partner AbbVie Inc. not to move forward with the asset, amid a market for anti-BCMA drugs that has become increasingly crowded.

The South San Francisco, CA-based biotech company said 13 September that AbbVie had decided not to exercise its exclusive license...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immuno-oncology

More from Anticancer